Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 19/20 | 0.48 |
| ▸ | RARG | P13631 | 19/20 | 0.48 |
| ▸ | RARA | P10276 | 16/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.48 |
| ▸ | CYP26A1 | O43174 | 2/20 | 0.48 |
| ▸ | CRABP2 | P29373 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7701222 | 0.96 | RARB (0.45) | RARBRARGRARACYP3A4CYP26A1 | |
| SCHEMBL7136046 | 0.90 | RARB (0.50) | RARBRARGRARACYP3A4CYP26A1 | |
| SCHEMBL7701225 | 0.88 | RARB (0.41) | RARBRARGRARACYP3A4CYP26A1 | |
| SCHEMBL7139166 | 0.84 | RARA (0.48) | RARBRARGRARACYP3A4CYP26A1 | |
| SCHEMBL7136227 | 0.84 | RARA (0.48) | RARBRARGRARACYP3A4CYP26A1 | |
| SCHEMBL7140735 | 0.81 | RARB (0.40) | RARBRARGRARACYP3A4CYP26A1 | |
| SCHEMBL7140796 | 0.80 | RARB (0.48) | RARBRARGRARACYP3A4CYP26A1 | |
| SCHEMBL9007043 | 0.77 | RARB (0.67) | RARBRARGRARACYP3A4CYP26A1 | |
| SCHEMBL7139242 | 0.75 | — | — | |
| SCHEMBL7143918 | 0.74 | RARB (0.45) | RARBRARGRARACYP3A4CYP26A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1212316-B1 | BENZOPYRANS AND BENZOTHIOPYRANS AS RAR SELECTIVE RETINOID AGONISTS | HOFFMANN LA ROCHE (CH) | 2003-10-15 | — | — | EP | claimed |
| US-6479670-B1 | Selective retinoid acid receptor agonists | HOFFMANN-LA ROCHE INC. | 2002-11-12 | — | — | US | claimed |
| US-12104169-B2 | Chemical reprogramming to generate neuronal cells | THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J. DAVID GLADSTONE (US) | 2024-10-01 | — | — | US | disclosed |
| US-20220243173-A1 | CHEMICAL REPROGRAMMING TO GENERATE NEURONAL CELLS | THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J. DAVID GLADSTONE | 2022-08-04 | — | — | US | disclosed |
| US-10980778-B2 | Methods for treating multiple osteochondroma (MO) | Clementia Pharmaceuticals Inc. (CA) | 2021-04-20 | — | — | US | disclosed |
| EP-3039126-B1 | SMALL MOLECULE CELLULAR REPROGRAMMING TO GENERATE NEURONAL CELLS | THE J DAVID GLADSTONE INST A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J DAVID GLADSTONE (US) | 2019-10-09 | — | — | EP | disclosed |
| US-20190275005-A1 | METHODS FOR TREATING MULTIPLE OSTEOCHONDROMA (MO) | Clementia Pharmaceuticals Inc. (CA) | 2019-09-12 | — | — | US | disclosed |
| US-20190010451-A1 | CHEMICAL REPROGRAMMING TO GENERATE NEURONAL CELLS | THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J. DAVID GLADSTONE | 2019-01-10 | — | — | US | disclosed |
| EP-3331988-A1 | CHEMICAL REPROGRAMMING TO GENERATE NEURONAL CELLS | The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone (US) | 2018-06-13 | — | — | EP | disclosed |
| US-20180140637-A1 | EPIDERMAL NEURAL CREST STEM CELLS AS A SOURCE OF SCHWANN CELLS | SIEBER BLUM MAYA (US) | 2018-05-24 | — | — | US | disclosed |
| WO-2017027280-A1 | CHEMICAL REPROGRAMMING TO GENERATE NEURONAL CELLS | THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J. DAVID GLADSTONE (US) | 2017-02-16 | — | — | WO | disclosed |
| US-20160250260-A1 | SMALL MOLECULE CELLULAR REPROGRAMMING TO GENERATE NEURONAL CELLS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-09-01 | — | — | US | disclosed |
| EP-3039126-A2 | SMALL MOLECULE CELLULAR REPROGRAMMING TO GENERATE NEURONAL CELLS | The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone (US) | 2016-07-06 | — | — | EP | disclosed |
| WO-2015041809-A2 | SMALL MOLECULE CELLULAR REPROGRAMMING TO GENERATE NEURONAL CELLS | THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J. DAVID GLADSTONE (US) | 2015-03-26 | — | — | WO | disclosed |
| EP-1212316-B1 | BENZOPYRANS AND BENZOTHIOPYRANS AS RAR SELECTIVE RETINOID AGONISTS | HOFFMANN LA ROCHE (CH) | 2003-10-15 | — | — | EP | disclosed |
| US-6479670-B1 | Selective retinoid acid receptor agonists | HOFFMANN-LA ROCHE INC. | 2002-11-12 | — | — | US | disclosed |
| EP-1212316-A2 | BENZOPYRANS AND BENZOTHIOPYRANS AS RAR SELECTIVE RETINOID AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-06-12 | — | — | EP | disclosed |
| WO-2001014360-A2 | BENZOPYRANS AND BENZOTHIOPYRANS AS RAR SELECTIVE RETINOID AGONISTS | F. HOFFMAN-LA ROCHE AG (CH) | 2001-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180140637-A1 | EPIDERMAL NEURAL CREST STEM CELLS AS A SOURCE OF SCHWANN CELLS | NES, NCSTN, SOX18 | RARB 190/4885RARG 215/4885RARA 519/4885 |
| US-10980778-B2 | Methods for treating multiple osteochondroma (MO) | UTRN, VHL, SOST | RARB 1620/4885RARG 1720/4885RARA 1990/4885 |
| US-20220243173-A1 | CHEMICAL REPROGRAMMING TO GENERATE NEURONAL CELLS | CHAT, DCX, NES | RARB 4/4885RARG 10/4885RARA 29/4885 |
| US-12104169-B2 | Chemical reprogramming to generate neuronal cells | CHAT, DCX, NES | RARB 4/4885RARG 10/4885RARA 29/4885 |
| US-20190010451-A1 | CHEMICAL REPROGRAMMING TO GENERATE NEURONAL CELLS | CHAT, DCX, NES | RARB 4/4885RARG 10/4885RARA 29/4885 |
| US-20190275005-A1 | METHODS FOR TREATING MULTIPLE OSTEOCHONDROMA (MO) | UTRN, VHL, SOST | RARB 1620/4885RARG 1720/4885RARA 1990/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.